Court of Appeal decision in Teva v Novartis

[{“id”:”9wss78lwb93wxb”,”elType”:”container”,”settings”:{“flex_direction”:”column”},”elements”:[{“id”:”5820cba”,”elType”:”container”,”settings”:[],”elements”:[{“id”:”_9wss78lwb93x4p”,”elType”:”widget”,”settings”:{“editor”:”What does the Court of Appeal decision in Teva v Novartis mean for the future use and commercial value of Arrow declarations?

PG Partner Peter Damerell speaks to IAM about the court’s decision not to allow declarations requested purely to influence foreign proceedings, and how Arrow relief applications may still serve a useful commercial purpose to patentees going forward. Please read here.”,”drop_cap”:”no”,”typography_typography”:”custom”,”typography_letter_spacing”:{“unit”:”px”,”size”:”0″},”typography_font_size”:{“unit”:”px”,”size”:”18″},”size”:”18″,”typography_font_weight”:”400″,”typography_line_height”:{“unit”:”px”,”size”:”28″},”title_color”:”#4b2771″,”text_color”:”#4b2771″,”color”:”#4b2771″,”align”:”start”},”widgetType”:”text-editor”}],”isInner”:false}],”isInner”:false}]